Active	Status	Sponsor type	Region	Phase	Filter
2 Active 2 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oudiz, Ronald J
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)	Terminated	2/3	202	Europe, Canada, US, RoW	AV-101, Placebo	Aerovate Therapeutics, Aerovate Therapeutics, Inc.	Pulmonary Arterial Hypertension	08/24	08/24
NCT05977933: Assessing the Utility of Submaximal CPET in Treatment Management of PAH	Not yet recruiting	N/A	550	US	Shape II CPET	Shape Medical Systems, Inc., National Heart, Lung, and Blood Institute (NHLBI)	Pulmonary Arterial Hypertension	09/24	12/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Oudiz, Ronald J
IMPAHCT, NCT05036135 / 2021-001910-13: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)	Terminated	2/3	202	Europe, Canada, US, RoW	AV-101, Placebo	Aerovate Therapeutics, Aerovate Therapeutics, Inc.	Pulmonary Arterial Hypertension	08/24	08/24
NCT05977933: Assessing the Utility of Submaximal CPET in Treatment Management of PAH	Not yet recruiting	N/A	550	US	Shape II CPET	Shape Medical Systems, Inc., National Heart, Lung, and Blood Institute (NHLBI)	Pulmonary Arterial Hypertension	09/24	12/24